Cyclophosphamide Treatment Options

A collection of 2150 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the United States. Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.

Home

All Treatments

Cyclophosphamide

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

Featured Trial

Evaluating an Investigational Treatment for Hidradenitis Suppurativa

Recruiting

The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.

Conditions:

All Conditions

Hidradenitis suppurativa (Skin disorder)

Dermatology

Learn More

Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)

NCT02932956

Active Not Recruiting

This study enrolls patients who have GPC3-positive solid tumors currently. Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called GAP T cells, a new experimental treatment. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. Both antibodies and T cells have been used to treat patients with cancers. They have shown promise, but have not been strong enough to cure most patients. Investigators have found from previous research that they can put a new gene into T cells that will make them recognize cancer cells and kill them. In preclinical studies, the investigators made several genes called a chimeric antigen receptor (CAR), from an antibody called GC33 that recognizes glypican-3, a proteoglycan found on solid tumors including pediatric liver cancers (GPC3-CAR). This study will test T cells genetically engineered with a GPC3-CAR (GAP T cells) in patients with GPC3-positive solid tumors (currently only enrolling liver tumors). The GAP T cells are an investigational product not approved by the Food and Drug Administration. The purpose of this study is to find the biggest dose of GAP T cells that is safe, to see how long they last in the body, to learn what the side effects are and to see if the GAP T cells will help people with GPC3-positive solid tumors. This study enrolls patients who have GPC3-positive solid tumors (currently only enrolling liver tumors). Read Less

Gender:

ALL

Ages:

Between 1 year and 21 years

Trial Updated:

06/19/2024

Locations: Texas Children's Hospital, Houston, Texas

Conditions: Liver Cancer

Learn More ›

CAR-T Cells for HIV Infection

NCT04648046

Recruiting

This is a limited-center, open-label dose escalating phase I/IIa study of autologous T cells expressing LVgp120duoCAR molecules in people with HIV infection. It will follow a 3+3 design. Dose escalation decisions will be made when a minimum of three participants have completed the safety-evaluation period (45 days) at a given dose level. Cohort 1 will undergo infusion of a single low-dose regimen of LVgp120duoCAR-T cells. Cohort 2 will undergo non-ablative conditioning with cyclophosphamide, fol... Read More

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

06/17/2024

Locations: University of California, Davis, Sacramento, California +1 locations

Conditions: HIV Infections

Learn More ›

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

NCT04933617

Terminated

Background: Burkitt Lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) are aggressive B cell lymphomas. Frontline treatment does not always work. Researchers want to see if a combination of drugs can help. Objective: To learn if it is safe to give people with certain cancers copanlisib together with rituximab and combination chemotherapy dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R). Eligibility: People ages 18 and older wit... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/13/2024

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Germinal Center B-cell Type (GCB)

Learn More ›

Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin

NCT02096588

Terminated

Doxorubicin (Adriamycin), one of the drugs commonly used for the treatment of breast cancer, is in a class of medications called anthracyclines. Anthracyclines may cause heart damage that can lead to weakening of the heart muscle. This heart damage may happen right away or may occur many years after the anthracycline is given Simvastatin is an oral medication approved by the FDA to lower cholesterol. Simvastatin is in a class of medications called statins. Some research has shown that statins m... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/12/2024

Locations: Kimmel Cancer Center at Johns Hopkins at Sibley Memorial Hospital, Washington, District of Columbia +1 locations

Conditions: Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer

Learn More ›

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

NCT02650986

Active Not Recruiting

This phase I/IIa trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens 1 (NY-ESO-1) gene that have spread to other places in the body (advanced). A T cell is a type of immune cell that can recognize and kill abnormal cells of the body. Placing a modified gene for NY-ESO-1 into the patients' T cells in the laboratory and then giving them bac... Read More

Gender:

ALL

Ages:

12 years and above

Trial Updated:

06/11/2024

Locations: Roswell Park Cancer Institute, Buffalo, New York

Conditions: Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Synovial Sarcoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Fallopian Tube Carcinoma, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Metastatic Synovial Sarcoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Unresectable Melanoma, Unresectable Ovarian Carcinoma, Unresectable Synovial Sarcoma

Learn More ›

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

NCT04927884

Terminated

This is a phase 1b/2 open-label study to evaluate the safety and efficacy of sacituzumab govitecan-hziy in combination with chemoimmunotherapy (cyclophosphamide, N-803, and PD-L1 t-haNK) in subjects with Triple Negative Breast Cancer (TNBC) after at least 2 prior treatments for metastatic disease.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/11/2024

Locations: Hoag Memorial Hospital, Newport Beach, California

Conditions: Advanced Triple Negative Breast Cancer

Learn More ›

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

NCT00006721

Active Not Recruiting

RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing substances to them without harming normal cells. It is not yet known which monoclonal antibody plus combination chemotherapy regimen is more effective in treating non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is comparing 2 different monoclonal antibod... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/10/2024

Locations: Alaska Regional Hospital Cancer Center, Anchorage, Alaska +258 locations

Alaska Regional Hospital Cancer Center, Anchorage, Alaska

Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital, Fairbanks, Alaska

Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Fort Smith, Arkansas

Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas

Alta Bates Summit Comprehensive Cancer Center, Berkeley, California

Peninsula Medical Center, Burlingame, California

Marin Cancer Institute at Marin General Hospital, Greenbrae, California

Sutter Health - Western Division Cancer Research Group, Greenbrae, California

Desert Regional Medical Center Comprehensive Cancer Center, Palm Springs, California

University of California Davis Cancer Center, Sacramento, California

California Pacific Medical Center - California Campus, San Francisco, California

Stanford Cancer Center, Stanford, California

Sutter Solano Medical Center, Vallejo, California

Helen and Harry Gray Cancer Center at Hartford Hospital, Hartford, Connecticut

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia

Center for Cancer Care and Research at Watson Clinic, LLP, Lakeland, Florida

Sacred Heart Cancer Center at Sacred Heart Hospital, Pensacola, Florida

West Florida Cancer Institute at West Florida Hospital - Pensacola, Pensacola, Florida

Piedmont Hospital, Atlanta, Georgia

Northside Hospital Cancer Center, Atlanta, Georgia

Saint Joseph's Hospital of Atlanta, Atlanta, Georgia

CCOP - Atlanta Regional, Atlanta, Georgia

WellStar Cobb Hospital, Austell, Georgia

Charles B. Eberhart Cancer Center at DeKalb Medical Center, Decatur, Georgia

Dwight David Eisenhower Army Medical Center, Fort Gordon, Georgia

Northeast Georgia Medical Center, Gainesville, Georgia

Gwinnett Medical Center, Lawrenceville, Georgia

Kennestone Cancer Center at Wellstar Kennestone Hospital, Marietta, Georgia

Southern Regional Medical Center, Riverdale, Georgia

Pearlman Comprehensive Cancer Center at South Georgia Medical Center, Valdosta, Georgia

Tripler Army Medical Center, Honolulu, Hawaii

Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center, Boise, Idaho

Mountain States Tumor Institute at St. Luke's Regional Medical Center, Boise, Idaho

Saint Anthony's Hospital at Saint Anthony's Health Center, Alton, Illinois

Rush-Copley Cancer Care Center, Aurora, Illinois

St. Joseph Medical Center, Bloomington, Illinois

Graham Hospital, Canton, Illinois

Memorial Hospital, Carthage, Illinois

University of Illinois Cancer Center, Chicago, Illinois

University of Chicago Cancer Research Center, Chicago, Illinois

Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois

Eureka Community Hospital, Eureka, Illinois

Galesburg Clinic, PC, Galesburg, Illinois

Galesburg Cottage Hospital, Galesburg, Illinois

Mason District Hospital, Havana, Illinois

Veterans Affairs Medical Center - Hines, Hines, Illinois

Hopedale Medical Complex, Hopedale, Illinois

Joliet Oncology-Hematology Associates, Limited - West, Joliet, Illinois

McDonough District Hospital, Macomb, Illinois

Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois

Good Samaritan Regional Health Center, Mount Vernon, Illinois

Edward Hospital Cancer Center, Naperville, Illinois

BroMenn Regional Medical Center, Normal, Illinois

Community Cancer Center, Normal, Illinois

Community Hospital of Ottawa, Ottawa, Illinois

Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, Illinois

Cancer Treatment Center at Pekin Hospital, Pekin, Illinois

Proctor Hospital, Peoria, Illinois

CCOP - Illinois Oncology Research Association, Peoria, Illinois

Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria, Illinois

Methodist Medical Center of Illinois, Peoria, Illinois

OSF St. Francis Medical Center, Peoria, Illinois

Illinois Valley Community Hospital, Peru, Illinois

Perry Memorial Hospital, Princeton, Illinois

St. Margaret's Hospital, Spring Valley, Illinois

Regional Cancer Center at Memorial Medical Center, Springfield, Illinois

Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois

CCOP - Carle Cancer Center, Urbana, Illinois

St. Francis Hospital and Health Centers - Beech Grove Campus, Beech Grove, Indiana

Elkhart General Hospital, Elkhart, Indiana

Howard Community Hospital, Kokomo, Indiana

Center for Cancer Therapy at LaPorte Hospital and Health Services, La Porte, Indiana

Saint Anthony Memorial Health Centers, Michigan City, Indiana

Reid Hospital & Health Care Services, Richmond, Indiana

CCOP - Northern Indiana CR Consortium, South Bend, Indiana

Memorial Hospital of South Bend, South Bend, Indiana

Saint Joseph Regional Medical Center, South Bend, Indiana

Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa

Mercy Medical Center - Sioux City, Sioux City, Iowa

St. Luke's Regional Medical Center, Sioux City, Iowa

Cancer Center of Kansas, PA - Chanute, Chanute, Kansas

Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas

Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas

Cancer Center of Kansas-Independence, Independence, Kansas

Providence Medical Center, Kansas City, Kansas

Cancer Center of Kansas, PA - Kingman, Kingman, Kansas

Lawrence Memorial Hospital, Lawrence, Kansas

Southwest Medical Center, Liberal, Kansas

Cancer Center of Kansas, PA - Newton, Newton, Kansas

Menorah Medical Center, Overland Park, Kansas

Johnson County Radiation Therapy, Overland Park, Kansas

Cancer Center of Kansas, PA - Parsons, Parsons, Kansas

Cancer Center of Kansas, PA - Pratt, Pratt, Kansas

Cancer Center of Kansas, PA - Salina, Salina, Kansas

Tammy Walker Cancer Center at Salina Regional Health Center, Salina, Kansas

Shawnee Mission Medical Center, Shawnee Mission, Kansas

Cotton-O'Neil Cancer Center, Topeka, Kansas

Cancer Center of Kansas, PA - Wellington, Wellington, Kansas

Associates in Womens Health, PA - North Review, Wichita, Kansas

Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas

Cancer Center of Kansas, PA - Wichita, Wichita, Kansas

CCOP - Wichita, Wichita, Kansas

Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas

Wesley Medical Center, Wichita, Kansas

Cancer Center of Kansas, PA - Winfield, Winfield, Kansas

Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland

Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland

Lahey Clinic Medical Center - Burlington, Burlington, Massachusetts

Berkshire Hematology Oncology, PC, Pittsfield, Massachusetts

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

Battle Creek Health System Cancer Care Center, Battle Creek, Michigan

Bay Regional Medical Center, Bay City, Michigan

Mecosta County Medical Center, Big Rapids, Michigan

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan

Butterworth Hospital at Spectrum Health, Grand Rapids, Michigan

CCOP - Grand Rapids, Grand Rapids, Michigan

Lacks Cancer Center at Saint Mary's Health Care, Grand Rapids, Michigan

Holland Community Hospital, Holland, Michigan

Borgess Medical Center, Kalamazoo, Michigan

West Michigan Cancer Center, Kalamazoo, Michigan

Bronson Methodist Hospital, Kalamazoo, Michigan

Hackley Hospital, Muskegon, Michigan

Lakeland Regional Cancer Care Center - St. Joseph, Saint Joseph, Michigan

Oncology Care Associates, PLLC, Saint Joseph, Michigan

Munson Medical Center, Traverse City, Michigan

Metro Health Hospital, Wyoming, Michigan

University of Mississippi Cancer Clinic, Jackson, Mississippi

Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital, Cape Girardeau, Missouri

Saint Francis Medical Center, Cape Girardeau, Missouri

Saint Luke's Hospital, Chesterfield, Missouri

Veterans Affairs Medical Center - Columbia (Truman Memorial), Columbia, Missouri

Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri

Independence Regional Health Center, Independence, Missouri

Freeman Cancer Institute at Freeman Health System, Joplin, Missouri

St. John's Regional Medical Center, Joplin, Missouri

Truman Medical Center - Hospital Hill, Kansas City, Missouri

Saint Luke's Cancer Institute at Saint Luke's Hospital, Kansas City, Missouri

Kansas City Cancer Center at St. Joseph's Medical Mall, Kansas City, Missouri

St. Joseph Medical Center, Kansas City, Missouri

North Kansas City Hospital, Kansas City, Missouri

Parvin Radiation Oncology, Kansas City, Missouri

CCOP - Kansas City, Kansas City, Missouri

Radiation Oncology Associates of Kansas City at Northland Radiation Oncology Center, Kansas City, Missouri

Heartland Regional Medical Center, Saint Joseph, Missouri

Midwest Hematology Oncology Group, Incorporated, Saint Louis, Missouri

Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri

CCOP - St. Louis-Cape Girardeau, Saint Louis, Missouri

David C. Pratt Cancer Center at St. John's Mercy, Saint Louis, Missouri

CCOP - Cancer Research for the Ozarks, Springfield, Missouri

St. John's Regional Health Center, Springfield, Missouri

Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri

CCOP - Montana Cancer Consortium, Billings, Montana

Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana

Northern Rockies Radiation Oncology Center, Billings, Montana

St. Vincent Healthcare Cancer Care Services, Billings, Montana

Billings Clinic - Downtown, Billings, Montana

Bozeman Deaconess Cancer Center, Bozeman, Montana

St. James Healthcare Cancer Care, Butte, Montana

Big Sky Oncology, Great Falls, Montana

Great Falls Clinic - Main Facility, Great Falls, Montana

Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana

Not set, Great Falls, Montana

St. Peter's Hospital, Helena, Montana

Glacier Oncology, PLLC, Kalispell, Montana

Kalispell Medical Oncology at KRMC, Kalispell, Montana

Kalispell Regional Medical Center, Kalispell, Montana

Community Medical Center, Missoula, Montana

Guardian Oncology and Center for Wellness, Missoula, Montana

Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana

Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana

Good Samaritan Cancer Center at Good Samaritan Hospital, Kearney, Nebraska

UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska

Roswell Park Cancer Institute, Buffalo, New York

Tucker Center for Cancer Care at Orange Regional Medical Center, Middletown, New York

New York Weill Cornell Cancer Center at Cornell University, New York, New York

James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina

Duke Comprehensive Cancer Center, Durham, North Carolina

Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina

McDowell Cancer Center at Akron General Medical Center, Akron, Ohio

Mary Rutan Hospital, Bellefontaine, Ohio

Adena Regional Medical Center, Chillicothe, Ohio

Good Samaritan Hospital Cancer Treatment Center, Cincinnati, Ohio

Charles M. Barrett Cancer Center at University Hospital, Cincinnati, Ohio

Cleveland Clinic Cancer Center at Fairview Hospital, Cleveland, Ohio

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

Riverside Methodist Hospital Cancer Care, Columbus, Ohio

CCOP - Columbus, Columbus, Ohio

Grant Medical Center Cancer Care, Columbus, Ohio

Mount Carmel Health - West Hospital, Columbus, Ohio

Doctors Hospital at Ohio Health, Columbus, Ohio

Grandview Hospital, Dayton, Ohio

Good Samaritan Hospital, Dayton, Ohio

David L. Rike Cancer Center at Miami Valley Hospital, Dayton, Ohio

Samaritan North Cancer Care Center, Dayton, Ohio

Veterans Affairs Medical Center - Dayton, Dayton, Ohio

CCOP - Dayton, Dayton, Ohio

Grady Memorial Hospital, Delaware, Ohio

Blanchard Valley Medical Associates, Findlay, Ohio

Middletown Regional Hospital, Franklin, Ohio

Community Oncology Group at Cleveland Clinic Cancer Center, Independence, Ohio

Charles F. Kettering Memorial Hospital, Kettering, Ohio

Fairfield Medical Center, Lancaster, Ohio

St. Rita's Medical Center, Lima, Ohio

Strecker Cancer Center at Marietta Memorial Hospital, Marietta, Ohio

Licking Memorial Cancer Care Program at Licking Memorial Hospital, Newark, Ohio

Mercy Medical Center, Springfield, Ohio

Community Hospital of Springfield and Clark County, Springfield, Ohio

UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio

Mount Carmel St. Ann's Cancer Center, Westerville, Ohio

Clinton Memorial Hospital, Wilmington, Ohio

Cleveland Clinic - Wooster, Wooster, Ohio

Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia, Ohio

Genesis - Good Samaritan Hospital, Zanesville, Ohio

Legacy Mount Hood Medical Center, Gresham, Oregon

Providence Milwaukie Hospital, Milwaukie, Oregon

Legacy Good Samaritan Hospital & Comprehensive Cancer Center, Portland, Oregon

Providence Cancer Center at Providence Portland Medical Center, Portland, Oregon

Adventist Medical Center, Portland, Oregon

CCOP - Columbia River Oncology Program, Portland, Oregon

Providence St. Vincent Medical Center, Portland, Oregon

Legacy Emanuel Hospital and Health Center and Children's Hospital, Portland, Oregon

Legacy Meridian Park Hospital, Tualatin, Oregon

Roper St. Francis Cancer Center at Roper Hospital, Charleston, South Carolina

Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina

Palmetto Health South Carolina Cancer Center, Columbia, South Carolina

CCOP - Greenville, Greenville, South Carolina

Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas

UMC Southwest Cancer and Research Center, Lubbock, Texas

Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah

Lynchburg Hematology-Oncology Clinic, Lynchburg, Virginia

St. Joseph Cancer Center, Bellingham, Washington

Olympic Hematology and Oncology, Bremerton, Washington

St. Francis Hospital, Federal Way, Washington

Columbia Basin Hematology, Kennewick, Washington

Cascade Cancer Center at Evergreen Hospital Medical Center, Kirkland, Washington

Olympic Medical Center, Port Angeles, Washington

Good Samaritan Cancer Center, Puyallup, Washington

Valley Medical Center, Renton, Washington

CCOP - Virginia Mason Research Center, Seattle, Washington

Fred Hutchinson Cancer Research Center, Seattle, Washington

Harborview Medical Center, Seattle, Washington

Minor and James Medical, PLLC, Seattle, Washington

Group Health Central Hospital, Seattle, Washington

Swedish Cancer Institute at Swedish Medical Center - First Hill Campus, Seattle, Washington

Polyclinic First Hill, Seattle, Washington

University Cancer Center at University of Washington Medical Center, Seattle, Washington

Cancer Care Northwest - Spokane South, Spokane, Washington

Franciscan Cancer Center at St. Joseph Medical Center, Tacoma, Washington

Allenmore Hospital, Tacoma, Washington

CCOP - Northwest, Tacoma, Washington

MultiCare Regional Cancer Center at Tacoma General Hospital, Tacoma, Washington

St. Clare Hospital, Tacoma, Washington

Southwest Washington Medical Center Cancer Center, Vancouver, Washington

Wenatchee Valley Medical Center, Wenatchee, Washington

North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima, Washington

Schiffler Cancer Center at Wheeling Hospital, Wheeling, West Virginia

Welch Cancer Center at Sheridan Memorial Hospital, Sheridan, Wyoming

Conditions: Lymphoma

Learn More ›

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

NCT05269381

Recruiting

This phase I trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is designed target certain proteins (neoantigens) on individuals' tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/10/2024

Locations: Mayo Clinic in Florida, Jacksonville, Florida

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Cervical Carcinoma, Locally Advanced Endometrial Carcinoma, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Locally Advanced Merkel Cell Carcinoma, Locally Advanced Renal Cell Carcinoma, Locally Advanced Skin Squamous Cell Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Locally Advanced Unresectable Breast Carcinoma, Locally Advanced Unresectable Cervical Carcinoma, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Locally Advanced Unresectable Renal Cell Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Skin Squamous Cell Carcinoma, Stage III Cervical Cancer AJCC v8, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Cervical Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Hepatocellular Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma, Unresectable Renal Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma, Unresectable Triple-Negative Breast Carcinoma, Unresectable Urothelial Carcinoma

Learn More ›

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

NCT03277729

Active Not Recruiting

The purpose of this research is to find the best dose of genetically modified T-cells, to study the safety of this treatment, and to see how well it works in treating patients with B cell non-Hodgkin lymphoma that has come back (relapsed) or did not respond to previous treatment (refractory).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/10/2024

Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Recurrent Transformed B-cell Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Marginal Zone Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Recurrent Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma

Learn More ›

Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia

NCT04789408

Terminated

The goal of this clinical study is to learn more about the safety and dosing of the study drug, KITE-222, in participants with relapsed/refractory (r/r) acute myeloid leukemia (AML).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/07/2024

Locations: Stanford Cancer Center, Stanford, California +8 locations

Conditions: Acute Myeloid Leukemia

Learn More ›

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

NCT06412497

Recruiting

A phase II trial of a reduced intensity conditioned (RIC) allogeneic hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy) for idiopathic severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), acquired pure red cell aplasia (aPRCA), or acquired amegakaryocytic thrombocytopenia (aAT) utilizing population pharmacokinetic (popPK)-guided individual dosing of pre-transplant conditioning and differential dosing of low dose total body irradiation based on ag... Read More

Gender:

ALL

Ages:

Between 0 years and 75 years

Trial Updated:

06/06/2024

Locations: University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota

Conditions: Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria

Learn More ›

Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH

NCT04540380

Recruiting

The goal is to investigate the safety of the conditioning regimen, and its ability to induce donor/recipient lymphohematopoietic chimerism without Chimerism Transition Syndrome (CTS), which may result in donor-specific unresponsiveness (tolerance) to the renal allograft in the absence of maintenance immunosuppression.

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

06/04/2024

Locations: Massachusetts General Hospital, Boston, Massachusetts

Conditions: Renal Failure

Learn More ›